Gregor Krings

8PUBLICATIONS
85CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)AutoimmunityCancer diagnosisHaematological tumoursMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 26, 2026
Medical Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Stage I to III Breast Cancer: ASCO Living Guideline, Version 2026.1.0.

|Dec 28, 2025
Genetic and immunohistochemical studies identify recurrent ACTB mutations and PTEN alterations in tubular adenomas of the breast.

Hnin Ingyin, James P Solomon, Yuewei Li

|Dec 28, 2025
Tall cell carcinoma with reversed polarity of the breast harbouring IDH1 hotspot mutation: morphologic, immunohistochemical and genetic characterization of two cases.

Gregor Krings, Sherin Hashem, Marsha A Apushkin

|Dec 10, 2024
Serous-like breast carcinomas: immunophenotypic, genetic, and clinicopathologic characterization of a morphologically distinct group of tumours.

Gregor Krings, Eliah R Shamir, Marick Laé

|Jun 26, 2024
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170).

Edward Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro

|Dec 18, 2023
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.

Kathy S Albain, Christina Yau, Emanuel F Petricoin

Pageof 2

Frequent Collaborators

2 joint publications

Gregory R Bean

2 joint publications

Yunn-Yi Chen

1 joint publications

M Conijn

1 joint publications

Kathy S Albain